Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the
CARB-X is partnering with Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity
Premaitha Health has signed an agreement with a new laboratory partner to offer an NIPT screening solution in a new East Asian territory for Premaitha.
Basilea Pharmaceutica has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera (ceftobiprole) in China, Hong Kong and Macao (the Territory).
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries.
SillaJen and Lee’s Pharmaceutical Holdings have said that they’ve gotten the approval from the China Food and Drug Administration (CFDA) to get a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec, the PHOCUS study.
Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1
Ipsen’s third phase trial of Somatuline lead to Japan’s clearance for new indication, certain tumors
Ipsen’s partner Teijin Group healtcare’s Pharma Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET).
Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.